Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States — Food and Drug Administration & Medtronic

9 shared events · Importance 4 · Last updated Sep 16, 2026

Importance
4
Shared Events
9
Actions
1
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
82
Regulatory
United States — Food and Drug Administration: The FDA granted the clearance that enables U.S. commercialization of the LigaSure RAS Maryland instrument on the Hugo system, acting as the key regulatory gatekeeper for the event.
Medtronic: Medtronic is the central actor, receiving FDA clearance for the LigaSure RAS Maryland device on its Hugo RAS system, which expands its robotic surgery portfolio and could support future U.S. revenue growth.
Sep 16, 2026 · 6 articles
63
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration cleared ShortCut, which is central to the deal's value proposition, enabling its commercial use in the U.S.
Medtronic: Medtronic is the lead investor, committing up to $80 million and securing distribution and acquisition rights. The deal expands its structural heart portfolio and is viewed positively by the market, with shares up nearly 7%.
Sep 01, 2026 · 9 articles
60
Regulatory
United States — Food and Drug Administration: The FDA granted De Novo authorization to Abbott's device, establishing new regulatory standards for continuous ketone monitoring. This action expands the regulatory framework for diabetes technology.
Medtronic: Medtronic's MiniMed is collaborating on an exclusive integration with Abbott's dual glucose-ketone sensors, expected in 2027. This partnership may enhance its smart dosing systems.
Aug 25, 2026 · 21 articles
57
Regulatory
United States — Food and Drug Administration: The FDA granted De Novo marketing authorization for J&J's OTTAVA system, clearing it for multiple general surgery procedures. This regulatory action enables J&J's commercial launch in the US.
Medtronic: Medtronic's Hugo robot, approved last year, now faces additional competition from J&J's OTTAVA system in the robotic surgery market.
Jul 22, 2026 · 20 articles
55
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body to which CereVasc will submit a Premarket Approval (PMA) for its eShunt System, a critical step for commercialization in the US.
Medtronic: Medtronic participated in the Series C financing, showing its interest in CereVasc's eShunt System and potentially expanding its portfolio in neurological medical devices.
Jun 04, 2026 · 6 articles
49
Business
United States — Food and Drug Administration: RapidPulse plans to seek FDA approval for its system pending clinical data.
Medtronic: Medtronic co-led the round, gaining strategic access to innovative stroke technology.
Jul 16, 2026 · 6 articles
45
Business
United States — Food and Drug Administration: Regulatory body that cleared Hugo in the U.S., a milestone for Medtronic's robotics program.
Medtronic: Medtronic is the lead investor and distributor, expanding its surgical robotics portfolio with the Sentire system. The $700 million investment strengthens its competitive position and is expected to drive growth.
Sep 01, 2026 · 15 articles
0
Business
Apr 22, 2026 · 6 articles
0
Tech
Apr 25, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States — Food and Drug Administration and Medtronic interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.